C4 Therapeutics, Inc.
CCCC · NASDAQ
Market closed$3.69$0.110000 (+3.07%)After hours $3.72 · +0.81%
Key statistics
Previous close$3.58
Open$3.48
Day high$3.77
Day low$3.44
52-week high$5.17
52-week low$1.69
Market cap305.63M
Volume2.45M
Average volume3.18M
P/E ratio-3.10
Forward P/E—
EPS-1.19
Dividend yield0.00%
Market context
Why it moved
C4 Therapeutics (CCCC) edged higher likely on continued positive investor sentiment ahead of its anticipated earnings release in early August, with modest buying interest pushing the stock up within a broad intraday range on elevated volume.
What is happening
Recent company-specific developments and publisher coverage.
Stock Titan · June 11, 2026Heavily pretreated myeloma patients see durable responses on C4 oral therapyInvesting News Network · June 11, 2026C4 Therapeutics Presents Phase 1 Data at European Hematology Association 2026 Congress Highlighting Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader for Multiple Myeloma in Heavily Pretreated Relapsed/Refractory PopulationInvesting News Network · May 12, 2026C4 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business HighlightsReuters · April 10, 2026C4 Therapeutics, Roche expand partnership with new cancer deal worth over $1 billionStock Titan · April 9, 2026Roche expands C4T deal on a new cancer-drug approach worth $1B-plusClinical Trials Arena · March 26, 2026C4 Therapeutics begins dosing in Phase Ib trial for multiple myelomaInvesting.com · March 25, 2026C4 Therapeutics begins trial of cemsidomide with elranatamabClinical Trials Arena · February 24, 2026C4 Therapeutics doses first patient in MOMENTUM trial for multiple myeloma Mt Newswire · June 11, 2026C4 Therapeutics Reports 53% Response Rate for Cemsidomide at RP2D Benzinga · June 11, 2026C4 Therapeutics To Present Further Analysis From Fully Enrolled Phase 1 Trial Of Cemsidomide In Combination With Dexamethasone For Treatment Of RRMM At EHA 2026 Congress Benzinga · June 1, 2026Evercore ISI Group Maintains Outperform on C4 Therapeutics, Raises Price Target to $12 Benzinga · May 12, 2026C4 Therapeutics Q1 EPS $(0.20) Beats $(0.27) Estimate, Sales $6.152M Beat $3.333M Estimate Benzinga · April 9, 2026C4 Therapeutics Deepens Roche Alliance To Target Breakthrough Cancer Therapies Mt Newswire · April 9, 2026C4 Therapeutics Expands Roche Partnership to Develop Degrader-Antibody Conjugates Against Cancer Benzinga · April 9, 2026C4 Therapeutics Teams Up With Roche On New Cancer Drug Approach, Secures $20M Upfront, Eyes Over $1B In Future Milestones Mt Newswire · March 25, 2026C4 Therapeutics Doses First Patient in Phase 1b Trial of Multiple Myeloma Combination Treatment